Evidence map›Paper›PMID 39170459›Full record

ArticleHeliyon2024

Characterization of MSCs expressing islet neogenesis associated protein (INGAP): INGAP secretion and cell survival

Maria Petropavlovskaia, Beatrice Assouline-Thomas, Jessica Cuerquis, Jing Zhao, Shaun Violette-Deslauriers, Eni Nano, Nicoletta Eliopoulos, Lawrence Rosenberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria PetropavlovskaiaLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Beatrice Assouline-ThomasLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Jessica CuerquisLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Jing ZhaoLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Shaun Violette-DeslauriersLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Eni NanoLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Nicoletta EliopoulosLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.
Lawrence RosenbergLady Davis Institute for Medical Research, SMBD-Jewish General Hospital, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) are emerging as a new therapy for diabetes. Here we investigate the properties of MSCs engineered to express Islet Neogenesis Associated Protein (INGAP) previously shown to reverse diabetes in animal models and evaluate their potential for anti-diabetic applications in mice. Mouse bone marrow-derived MSCs retrovirally transduced to co-express INGAP, Firefly Luciferase and EGFP (INGAP-MSCs), were characterized

Indexed as

Adipogenic differentiationExtracellular matrixHydrogelIslet neogenesis associated protein (INGAP)Mesenchymal stem cells (MSCs)Mesenchymal stromal cells

Identifiers

PMID39170459
PMCPMC11336584

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.